Marketable Investments

12 Months Ended

Dec. 31, 2021

Investments, Debt and Equity Securities [Abstract]

Marketable Investments

Note 5. Marketable Investments

Investment in corporate debt securities and equity securities as of December 31, 2021 and 2020 consist of the following (in thousands):

	Year Ended December 31,
	2021		2020
Corporate debt securities	$	119	$	241
Equity securities		1,034		1,210
Total marketable investments	$	1,153	$	1,451

The amortized cost basis amounts, gross unrealized holding gains, gross unrealized holding losses and fair values of available-for-sale debt securities as of December 31, 2021 and 2020, are as follows (in thousands):

December 31, 2021	Amortized Cost		Gross Unrealized Gains		Gross Unrealized Losses		Fair Value
Corporate debt securities	$	119	$	—	$	—	$	119
December 31, 2020	Amortized Cost		Gross Unrealized Gains		Gross Unrealized Losses		Fair Value
Corporate debt securities	$	241	$	—	$	—	$	241

The following table presents realized and unrealized gains and losses on equity securities as prescribed by ASC 321, Investment - Equity Securities during the year ended December 31, 2021 and 2020.

	December 31,
	2021			2020
Unrealized net gain (loss) on equity securities reflected in the Consolidated Statements of Income	$	1,839		$	(591	)
Proceeds received on tender of equity securities		1,875			—
Realized loss on tender/sale of equity securities reflected in the Consolidated Statements of Income		(140	)		—

Equity Securities

On October 29, 2021, Misonix, Inc. (“Misonix”) was acquired by Bioventus, Inc. (“Bioventus”). Upon closing of the transaction, the Company tendered its Misonix common stock and received $1.9 million in cash and 71,361 shares of Bioventus common stock, which are reflected at their estimated fair value of $1.0 million as of December 31, 2021. The Company recognized a $0.1 million realized loss on the tender of the Misonix common stock.